Skip to main content
Top
Published in: Supportive Care in Cancer 10/2014

01-10-2014 | Original Article

Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?

Authors: Gianmauro Numico, Antonio Trogu, Antonella Cristofano, Alessandro Mozzicafreddo, Giulia Courthod, Pierfrancesco Franco, Nicola Silvestris

Published in: Supportive Care in Cancer | Issue 10/2014

Login to get access

Abstract

Purpose

Chemotherapy near the end of life is frequently considered as an indicator of inappropriate aggressiveness. We were interested in revising our prescribing habits and in analyzing the reasons for offering active treatment to patients with advanced cancer.

Methods

We examined the electronic medical records of all the cancer patients died in the Italian Region of Valle d’Aosta in a 1-year period and extracted all the available clinical data. From the 350 deceased patients, we selected the 141 to whom active treatment had been given during the natural history of their disease.

Results

Among the patients undergoing any active treatment, the median number of days from the last administration to death was 75. Thirty-seven patients (26.2 %) had their last treatment administration during the 4 weeks before death and 20 (14.2 %) during the last 2 weeks. Fourteen patients (9.9 %) started treatment during the last 4 weeks. When the patients undergoing treatment in the last 4 weeks of life were compared with those subject to earlier withdrawal, only age and pretreatment were statistically significantly different. Most of the treatment choices were considered appropriate, and earlier treatment withdrawal could have been advised only in a minority of the cases.

Conclusions

Our data were at the lower range when compared with the available literature. Uncertainties in prognostication and the possibility of response to treatment can justify chemotherapy prescriptions in selected cases. We suggest that the focus should move to the provision of adequate and timely supportive care.
Literature
1.
go back to reference Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22:315–321PubMedCrossRef Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22:315–321PubMedCrossRef
2.
go back to reference Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ (2008) Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 26:3860–3866PubMedCentralPubMedCrossRef Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ (2008) Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 26:3860–3866PubMedCentralPubMedCrossRef
4.
go back to reference Nappa U, Lindqvist O, Rasmussen BH, Xelsson B (2011) Palliative chemotherapy during the last month of life. Ann Oncol 22:2375–2380PubMedCrossRef Nappa U, Lindqvist O, Rasmussen BH, Xelsson B (2011) Palliative chemotherapy during the last month of life. Ann Oncol 22:2375–2380PubMedCrossRef
5.
go back to reference Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Blok S (2003) Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 21:1133–1138PubMedCrossRef Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Blok S (2003) Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 21:1133–1138PubMedCrossRef
6.
go back to reference Numico G, Russi E, Merlano M (2001) Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy? Lung Cancer 32:213–226PubMedCrossRef Numico G, Russi E, Merlano M (2001) Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy? Lung Cancer 32:213–226PubMedCrossRef
7.
go back to reference Stinnett S, Williams L, Johnson DH (2007) Role of chemotherapy for palliation in the lung cancer patient. J Support Oncol 5:19–24PubMed Stinnett S, Williams L, Johnson DH (2007) Role of chemotherapy for palliation in the lung cancer patient. J Support Oncol 5:19–24PubMed
8.
go back to reference Archer VR, Billingham LJ, Cullen MH (1999) Palliative chemotherapy: no longer a contradiction in terms. Oncologist 4:470–477PubMed Archer VR, Billingham LJ, Cullen MH (1999) Palliative chemotherapy: no longer a contradiction in terms. Oncologist 4:470–477PubMed
9.
go back to reference Langer CJ (2009) The “Lazarus response” in treatment-naïve, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol 27:1350–1354PubMedCrossRef Langer CJ (2009) The “Lazarus response” in treatment-naïve, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol 27:1350–1354PubMedCrossRef
10.
go back to reference Numico G, Occelli M, Russi EG et al (2011) Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and Pap score. Supp Cancer 19:1823–1830CrossRef Numico G, Occelli M, Russi EG et al (2011) Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and Pap score. Supp Cancer 19:1823–1830CrossRef
11.
go back to reference Earle CC, Neville BA, Landrum MB et al (2005) Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care 17:505–509PubMedCrossRef Earle CC, Neville BA, Landrum MB et al (2005) Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care 17:505–509PubMedCrossRef
12.
go back to reference Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639–643PubMedCrossRef Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639–643PubMedCrossRef
13.
go back to reference Ho TH, Barbera L, Saskin R, Lu H, Neville BA, Earle CC (2011) Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 29:1587–1591PubMedCentralPubMedCrossRef Ho TH, Barbera L, Saskin R, Lu H, Neville BA, Earle CC (2011) Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 29:1587–1591PubMedCentralPubMedCrossRef
14.
go back to reference Yun YH, Kwak M, Park SM et al (2007) Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 72:164–171PubMedCrossRef Yun YH, Kwak M, Park SM et al (2007) Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 72:164–171PubMedCrossRef
15.
go back to reference Gonsalves WI, Tashi T, Krishnamurthy J et al (2011) Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran’s Affairs cancer population. J Palliat Med 14:1231–1235PubMedCrossRef Gonsalves WI, Tashi T, Krishnamurthy J et al (2011) Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran’s Affairs cancer population. J Palliat Med 14:1231–1235PubMedCrossRef
16.
go back to reference Kao S, Shafiq J, Vardy J, Adams D (2009) Use of chemotherapy at the end of life in oncology patients. Ann Oncol 20:1555–1559PubMedCrossRef Kao S, Shafiq J, Vardy J, Adams D (2009) Use of chemotherapy at the end of life in oncology patients. Ann Oncol 20:1555–1559PubMedCrossRef
17.
go back to reference Braga S, Miranda A, Fonseca R et al (2007) The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Psychooncology 16:863–868PubMedCrossRef Braga S, Miranda A, Fonseca R et al (2007) The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Psychooncology 16:863–868PubMedCrossRef
18.
go back to reference Martoni AA, Tanneberger S, Mutri V (2007) Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori 93:417–422PubMed Martoni AA, Tanneberger S, Mutri V (2007) Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori 93:417–422PubMed
19.
go back to reference Murillo JR, Koeller J (2006) Chemotherapy given near the end of life by community oncologists for advanced non small cell lung cancer. Oncologist 11:1095–1099PubMedCrossRef Murillo JR, Koeller J (2006) Chemotherapy given near the end of life by community oncologists for advanced non small cell lung cancer. Oncologist 11:1095–1099PubMedCrossRef
20.
go back to reference Asola R, Huhtala H, Holli K (2006) Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer. Breast Cancer Res Treat 100:77–82PubMedCrossRef Asola R, Huhtala H, Holli K (2006) Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer. Breast Cancer Res Treat 100:77–82PubMedCrossRef
21.
go back to reference Magarotto R, Lunardi G, Coati F et al (2011) Reduced use of chemotherapy at the end of life in an integrated-care model of oncology and palliative care. Tumori 97:573–577PubMed Magarotto R, Lunardi G, Coati F et al (2011) Reduced use of chemotherapy at the end of life in an integrated-care model of oncology and palliative care. Tumori 97:573–577PubMed
22.
go back to reference Andreis F, Rizzi A, Rota L, Meriggi F, Mazzocchi M, Zaniboni A (2011) Chemotherapy use at the end of life. A retrospective single centre experience analysis. Tumori 97:30–34PubMed Andreis F, Rizzi A, Rota L, Meriggi F, Mazzocchi M, Zaniboni A (2011) Chemotherapy use at the end of life. A retrospective single centre experience analysis. Tumori 97:30–34PubMed
23.
go back to reference Greer JA, Pirl WF, Jackson VA et al (2012) Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 30:394–400PubMedCrossRef Greer JA, Pirl WF, Jackson VA et al (2012) Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 30:394–400PubMedCrossRef
24.
go back to reference Baldotto CS, Cronrmberger EH, De Biasi P et al (2012) Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy? Support Care Cancer 20:2721–2727PubMedCrossRef Baldotto CS, Cronrmberger EH, De Biasi P et al (2012) Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy? Support Care Cancer 20:2721–2727PubMedCrossRef
25.
go back to reference Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490–3496PubMedCrossRef Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490–3496PubMedCrossRef
26.
go back to reference Numico G, Anfossi M, Bertelli G et al (2009) The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer. Ann Oncol 20:941–945PubMedCrossRef Numico G, Anfossi M, Bertelli G et al (2009) The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer. Ann Oncol 20:941–945PubMedCrossRef
27.
28.
go back to reference Kiely BE, Martin AJ, Tattersall MHN et al (2013) The median informs the message: accuracy of individualized scenarios for survival time based on oncologists’ estimates. J Clin Oncol 31:3565–3571PubMedCrossRef Kiely BE, Martin AJ, Tattersall MHN et al (2013) The median informs the message: accuracy of individualized scenarios for survival time based on oncologists’ estimates. J Clin Oncol 31:3565–3571PubMedCrossRef
29.
go back to reference Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742PubMedCrossRef Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742PubMedCrossRef
30.
go back to reference Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH (2012) Health care costs for patients with cancer at the end of life. J Oncol Pract 8:75–80CrossRef Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH (2012) Health care costs for patients with cancer at the end of life. J Oncol Pract 8:75–80CrossRef
Metadata
Title
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?
Authors
Gianmauro Numico
Antonio Trogu
Antonella Cristofano
Alessandro Mozzicafreddo
Giulia Courthod
Pierfrancesco Franco
Nicola Silvestris
Publication date
01-10-2014
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2268-2

Other articles of this Issue 10/2014

Supportive Care in Cancer 10/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine